Exhibitors

Exhibitor Sponsored Presentations


September 25, 2017

07:00–08:00

Axion BioSystems

Salon 4 London

Get ready to LEAP: Advances in Automated Arrhythmia Detection for Next-Generation hiPSC-CM MEA Assays

Trends in cardiac safety testing, as exemplified by CiPA and JiCSA, emphasize a move beyond surrogate measures of Proarrhythmia. The cardiomyocyte and multiwell microelectrode array (CM-MEA) assay offers an ideal approach to evaluate pre-arrhythmic indicators in vitro. Join Axion BioSystems to discuss advances in automated arrhythmia detection using Local Extracellular Action Potential (LEAP) technology to support next-generation CM-MEA assays.


07:00–08:00

Elsevier

Salon 5 London

Leverage Drug Approval Precedents, Unique FAERS Search Aapabilities and a Powerful DDI Risk Calculator to Inform Preclinical and Clinical Development Decisions

Join Elsevier for a discussion on how to leverage drug approval precedents, including information on drug safety, pharmacokinetic and metabolizing & transporter data to help address safety assessment questions that often arise during development. Elsevier will also introduce how identifying and analyzing drug-drug interactions (DDI), along with mining through information in FAERS reports support drug safety and risk mitigation decisions.


12:30–13:30

Coyne Scientific

Salon 4 London

Rethinking In Vitro Safety & Toxicity Testing: Leveraging Genetic Diversity to Reduce Clinical Attrition

Coyne Scientific, an emerging biotech services company, invites you to discover how using hiPSC-derived cardiomyocytes obtained from a cohort of genetically-diversified individuals (rather than a single individual) can significantly improve the assessment of cardiac toxicity of pharmaceuticals within a target population and potentially reduce attrition of compounds in clinical development.


12:30–13:30

emka TECHNOLOGIES

Salon 5 London

Identify, Evaluate, Investigate - Pushing the Boundaries of ICH S7A Beyond QT & Advanced Seizure Detection

Simon Authier, DVM, MBA, PhD, DSP, Senior Director of Scientific Operations and Veterinary Science/Deputy Chief Scientific Officer at CiToxLAB, will present data and insights from his recent experiments using implanted telemetry for ECG and EEG analysis:

  • JTp and Tpe as biomarkers of proarrhythmic risk in non-clinical models: Historical Data Evaluation by the HESI Consortium
  • Exploring Natural Characteristics of Epileptiform EEG & Considerations for Seizure Liability Analysis

18:00–19:00

Data Sciences International (DSI)

Salon Dublin

DSI's 10th Annual Data Blast

Join us for an evening of education and entertainment at DSI’s 10th Annual Scientific Data Blast. Network and enjoy a cocktail while your colleagues present their latest scientific discoveries in an abbreviated format. Refreshments will be served.


18:00–19:00

ACEA Biosciences

Salon 4 London

Functional Enhancement of Human iPSC-derived Cardiomyocytes Enabling Assessment of Inotropic Compounds and Improved Prediction of Compound Risk

We will discuss the utility of iCell2 Cardiomyocyte and the xCELLigence CardioECR System for safety and drug discovery applications. We will focus on functional enhancement of iCell2 Cardiomyocytes using electrical pacing enabling assessment of positive inotrpic compounds. Improved predictivity of functionally enhanced cardiomyocytes for risk assessment will also be discussed.


September 26, 2017

07:00–08:00

Charles River

Salon 4 London

Exploring Best Practices in Rodent Neurobehavioral Assessments

Despite requirements for preclinical behavioural assessments, CNS-related safety concerns remain a major contributor to attrition in drug development. In this session, industry experts will examine current methodologies, discuss best practices and establish appropriate training requirements for conducting neurobehavioral assessments.
We invite you to join the conversation and enjoy a complimentary breakfast.


07:00–08:00

Cellular Dynamics International, a FUJIFILM company

Salon 5 London

Human-based Seizurogenic Assays: Using iPSC-derived Glutamatergic Neurons to Assess Drug-induced Changes in Network Activity

iCell Glutamatergic Neurons are iPSC-derived human excitatory neurons that form spontaneously bursting networks modulated by pro-convulsant and neuroactive molecules, thus adding a new dimension to the toxicologist’s toolbox. This workshop will illustrate the attributes of these neurons, provide case studies highlighting their use, and illustrate potential analyses for pro-seizurogenic investigations.


12:30–13:30

Clyde Biosciences

Salon 4 London

Advances in Cardiac Screening - All-optical Functional Assessment of Cardiotoxicity and Efficacy

The advantages of optical techniques to assess the acute and chronic effects of drugs on cardiomyocyte function will be discussed; including applications to single cells, sheets of cells and 3D microtissues. Uniquely, CellOPTIQ ® uses ratiometric optical techniques to record transmembrane voltage and intracellular calcium. Cell contractility is directly measured from cell movement.


12:30–13:30

Data Sciences International (DSI)

Salon 5 London

Guinea to Mini: Incorporation of “Pigs” into Safety Pharmacology and Toxicology Assessments

Guinea pigs and minipigs are increasingly used animal models in Safety Pharmacology and Toxicology studies. Brian Roche of Charles River, Ashland and Olivier Meyer of CRL UK will discuss the use of guinea pigs and minipigs respectively in cardiovascular safety and toxicology assessments utilizing in vivo physiologic monitoring. Lunch provided.


18:00–19:00

DiscoverX

Salon 5 London

SAFETYscan™ Functional In Vitro Pharmacological Profiling

In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles with the aim of reducing attrition in drug discovery and candidate selection processes. SAFETYscan™ offers a broad menu, including assays for targets recommended by major pharmaceutical companies (Bowes et.al. 2012) linked to major safety liabilities. All SAFETYscan assays are human orthologs and provide functional data for cell surface receptors, ion channels and transporters. Assessing the specificity of lead compounds early in development using highly relevant and predictive assays allows more informed decisions about compound safety, ultimately leading to the development of safer and more effective drugs.
Case studies on the application of SAFETYscan™ in in vitro pharmacological profiling will be discussed.


18:00–19:00

TSE Systems

Salon 3 Rom

A New Telemetry-based System for Assessing Cardiovascular Function in Large Animals-Part II, Pharmacological Validation by M. Markert, Boehringer Ingelheim

A first pharmacological evaluation of a newly developed total implant telemetry system for cardiovascular (CV), electrophysiological and body temperature measurement. It is intended to be used for drug candidate safety pharmacological evaluations.


18:00–19:00

myriamed GmbH

Salon 4 London

Innovative Platforms for Phenotypic Drug Screens in Engineered Macro Tissues

Engineered macro tissues provide the unique opportunity to test therapeutic interventions in a patient centric approach with the possibility to provide preclinical proof-of-concept for expedited clinical development. Advances in the engineering of heart muscle, skeletal muscle, brain and fibrotic tissue for phenotypic screens of wanted and unwanted drug effects will be discussed.


Exhibitor Information

Please visit the Exhibits Website to book your booth, view the exhibitor directory and more!